These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

55 related articles for article (PubMed ID: 7546904)

  • 1. Preparation and characterization of human HIV type 1 neutralizing reference sera.
    Vujcic LK; Quinnan GV
    AIDS Res Hum Retroviruses; 1995 Jul; 11(7):783-7. PubMed ID: 7546904
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HIV-1 inhibitory properties of eCD4-Igmim2 determined using an Env-mediated membrane fusion assay.
    Yang E; Gardner MR; Zhou AS; Farzan M; Arvin AM; Oliver SL
    PLoS One; 2018; 13(10):e0206365. PubMed ID: 30359435
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tetherin Antagonism by HIV-1 Group M Nef Proteins.
    Arias JF; Colomer-Lluch M; von Bredow B; Greene JM; MacDonald J; O'Connor DH; Serra-Moreno R; Evans DT
    J Virol; 2016 Dec; 90(23):10701-10714. PubMed ID: 27654287
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of HIV Entry by Targeting the Envelope Transmembrane Subunit gp41.
    Yi HA; Fochtman BC; Rizzo RC; Jacobs A
    Curr HIV Res; 2016; 14(3):283-94. PubMed ID: 26957202
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tetherin antagonism by Vpu protects HIV-infected cells from antibody-dependent cell-mediated cytotoxicity.
    Arias JF; Heyer LN; von Bredow B; Weisgrau KL; Moldt B; Burton DR; Rakasz EG; Evans DT
    Proc Natl Acad Sci U S A; 2014 Apr; 111(17):6425-30. PubMed ID: 24733916
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Soluble HIV-1 envelope immunogens derived from an elite neutralizer elicit cross-reactive V1V2 antibodies and low potency neutralizing antibodies.
    Carbonetti S; Oliver BG; Glenn J; Stamatatos L; Sather DN
    PLoS One; 2014; 9(1):e86905. PubMed ID: 24466285
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sub-inhibitory concentrations of human α-defensin potentiate neutralizing antibodies against HIV-1 gp41 pre-hairpin intermediates in the presence of serum.
    Demirkhanyan L; Marin M; Lu W; Melikyan GB
    PLoS Pathog; 2013; 9(6):e1003431. PubMed ID: 23785290
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neutralizing antibody responses in macaques induced by human immunodeficiency virus type 1 monovalent or trivalent envelope glycoproteins.
    Quinnan GV; Zhang P; Dong M; Chen H; Feng YR; Lewis M; Broder CC
    PLoS One; 2013; 8(3):e59803. PubMed ID: 23533650
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Outer domain of HIV-1 gp120: antigenic optimization, structural malleability, and crystal structure with antibody VRC-PG04.
    Joyce MG; Kanekiyo M; Xu L; Biertümpfel C; Boyington JC; Moquin S; Shi W; Wu X; Yang Y; Yang ZY; Zhang B; Zheng A; Zhou T; Zhu J; Mascola JR; Kwong PD; Nabel GJ
    J Virol; 2013 Feb; 87(4):2294-306. PubMed ID: 23236069
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Human CRM1 augments production of infectious human and feline immunodeficiency viruses from murine cells.
    Elinav H; Wu Y; Coskun A; Hryckiewicz K; Kemler I; Hu Y; Rogers H; Hao B; Ben Mamoun C; Poeschla E; Sutton R
    J Virol; 2012 Nov; 86(22):12053-68. PubMed ID: 22933280
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Broadly neutralizing antibodies present new prospects to counter highly antigenically diverse viruses.
    Burton DR; Poignard P; Stanfield RL; Wilson IA
    Science; 2012 Jul; 337(6091):183-6. PubMed ID: 22798606
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Direct phenotypical and functional dysregulation of primary human B cells by human immunodeficiency virus (HIV) type 1 in vitro.
    Perisé-Barrios AJ; Muñoz-Fernandez MÁ; Pion M
    PLoS One; 2012; 7(7):e39472. PubMed ID: 22768302
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enhanced macrophage tropism of HIV in brain and lymphoid tissues is associated with sensitivity to the broadly neutralizing CD4 binding site antibody b12.
    Dunfee RL; Thomas ER; Gabuzda D
    Retrovirology; 2009 Jul; 6():69. PubMed ID: 19619305
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antibody elicited against the gp41 N-heptad repeat (NHR) coiled-coil can neutralize HIV-1 with modest potency but non-neutralizing antibodies also bind to NHR mimetics.
    Nelson JD; Kinkead H; Brunel FM; Leaman D; Jensen R; Louis JM; Maruyama T; Bewley CA; Bowdish K; Clore GM; Dawson PE; Frederickson S; Mage RG; Richman DD; Burton DR; Zwick MB
    Virology; 2008 Jul; 377(1):170-83. PubMed ID: 18499210
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The membrane-proximal external region of the human immunodeficiency virus type 1 envelope: dominant site of antibody neutralization and target for vaccine design.
    Montero M; van Houten NE; Wang X; Scott JK
    Microbiol Mol Biol Rev; 2008 Mar; 72(1):54-84, table of contents. PubMed ID: 18322034
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predominant mode of human immunodeficiency virus transfer between T cells is mediated by sustained Env-dependent neutralization-resistant virological synapses.
    Chen P; Hübner W; Spinelli MA; Chen BK
    J Virol; 2007 Nov; 81(22):12582-95. PubMed ID: 17728240
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structure and function of the HIV envelope glycoprotein as entry mediator, vaccine immunogen, and target for inhibitors.
    Prabakaran P; Dimitrov AS; Fouts TR; Dimitrov DS
    Adv Pharmacol; 2007; 55():33-97. PubMed ID: 17586312
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dissecting the neutralizing antibody specificities of broadly neutralizing sera from human immunodeficiency virus type 1-infected donors.
    Dhillon AK; Donners H; Pantophlet R; Johnson WE; Decker JM; Shaw GM; Lee FH; Richman DD; Doms RW; Vanham G; Burton DR
    J Virol; 2007 Jun; 81(12):6548-62. PubMed ID: 17409160
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cross-reactive HIV-1 neutralizing monoclonal antibodies selected by screening of an immune human phage library against an envelope glycoprotein (gp140) isolated from a patient (R2) with broadly HIV-1 neutralizing antibodies.
    Choudhry V; Zhang MY; Sidorov IA; Louis JM; Harris I; Dimitrov AS; Bouma P; Cham F; Choudhary A; Rybak SM; Fouts T; Montefiori DC; Broder CC; Quinnan GV; Dimitrov DS
    Virology; 2007 Jun; 363(1):79-90. PubMed ID: 17306322
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An affinity-enhanced neutralizing antibody against the membrane-proximal external region of human immunodeficiency virus type 1 gp41 recognizes an epitope between those of 2F5 and 4E10.
    Nelson JD; Brunel FM; Jensen R; Crooks ET; Cardoso RM; Wang M; Hessell A; Wilson IA; Binley JM; Dawson PE; Burton DR; Zwick MB
    J Virol; 2007 Apr; 81(8):4033-43. PubMed ID: 17287272
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.